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Discrete and punctate nuclear RNA foci are characteristic molecular hallmarks of pathogenesis in myotonic
dystrophy type 1 and type 2. Intranuclear RNA inclusions of distinct morphology have also been found in
fragile X-associated tremor ataxia syndrome, Huntington’s disease-like 2, spinocerebellar ataxias type 8,
type 10 and type 31. These neurological diseases are associated with the presence of abnormally long
simple repeat expansions in their respective genes whose expression leads to the formation of ﬂawed tran-
scripts with altered metabolisms. Expanded CUG, CCUG, CGG, CAG, AUUCU and UGGAA repeats are associ-
ated with the diseases and accumulate in nuclear foci, as demonstrated in variety of cells and tissues of
human and model organisms. These repeat RNA foci differ in size, shape, cellular abundance and protein
composition and their formation has a negative impact on cellular functions. This review summarizes the
efforts of many laboratories over the past 15 years to characterize nuclear RNA foci that are recognized as
important triggers in the mutant repeat RNA toxic gain-of-function mechanisms of pathogenesis in neurologi-
cal disorders.
INTRODUCTION
Expansions of short tandem repeat of tri-, tetra- and pentanu-
cleotides in single genes cause hereditary neurological dis-
eases in humans. The abnormally expanded microsatellites
can lead to a variety of effects on genes, including the inhi-
bition of transcription and the loss-of-function of protein pro-
ducts. In several cases, the repeat expansions confer toxicity to
the mutant transcripts and to the encoded proteins, both of
which are capable of disrupting cell functions, leading to
disease.
The discovery that RNA harboring CUG repeat expansion is
retained in the cell nucleus, where it colocalizes with some
host proteins and forms microscopic ribonuclear inclusions
(1,2), had far-reaching consequences for research in the ﬁeld
of neurological disorders. While transcripts are normally des-
tined to deliver the message from the DNA sequence to the
cytoplasm for protein expression, abnormally lengthened
repeats of the mutant myotonic dystrophy type 1 (DM1) tran-
script become aberrantly recognized by cellular machinery and
pick up an excess of speciﬁc proteins, resulting in the nuclear
retention of the RNA (1,3,4). In addition to DM1, various
microsatellite expansions present in the transcripts of different
genes associated with myotonic dystrophy type 2 (DM2),
fragile X-associated tremor ataxia syndrome (FXTAS), Hun-
tington’s disease-like 2 (HDL2), spinocerebellar ataxias type
8 (SCA8), type 31 (SCA31) and type 10 (SCA10) have also
been shown to gain nuclear toxicity (5–10).
Molecular hallmarks of cells expressing expanded repeat
RNA are nuclear RNA foci of distinct morphology and abun-
dance. The type of tissue, the expression level of the repeat-
containing transcript and the repertoire and abundance of the
expressed proteins may inﬂuence foci size, shape, colocaliza-
tion with proteins and intensity of ﬂuorescence when
measured by ﬂuorescence in situ hybridization (FISH). Pre-
sumably, RNA repeat inclusions are trapped in the nucleus
due to their abnormal cargo, which is composed of dozens
of molecules of ﬂawed RNA (11) overloaded with proteins
(12–15) that non-speciﬁcally interact with expanded repeats.
Such interactions may lead to robust sequestration of the pro-
teins, as detected for muscleblind 1 (MBNL1) (12), may lead
to the recruitment of proteins to RNA foci with limited colo-
calization, as shown for hnRNP H (16), or may only represent
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insight into dynamics of CUG repeat foci has revealed that
these are unstable, constantly aggregating and disaggregating
structures, and that MBNL1 is directly involved in the stochas-
tic process of foci formation (18). This indicates that CUG
repeat foci are formed not just by transcript self-aggregation
but the process involves protein immobilization including
MBNL1. Whether similar behavior of transcript self-
aggregation is part of RNA foci formation by other repeats
needs to be resolved. In general, the presence of RNA foci
has an adverse effect on host cells, which leads to abnormal-
ities in distinct cellular pathways, including the activation of
apoptosis and aberrant alternative splicing (9,19). The
muscleblind-like family (MBNL1, MBNL2 and MBNL3),
Sam68 and hnRNP K are among the proteins implicated in
foci RNA-mediated pathogenesis due to their abnormal inter-
actions with mutant repeats. Whereas MBNL1 is detected in a
variety of repeat-formed foci, including CUG, CCUG, CAG
and CGG RNA inclusions, Sam68 has only been found in
expanded CGG repeat RNA (5,12,20–23), and hnRNP K is
associated in situ with the AUUCU mutation of SCA10 (9).
Fluorescence in situ hybridization enables the localization
of speciﬁc sequences of nucleic acids directly inside cells or
tissue (1). Using FISH antisense probes that hybridize to
RNA transcripts has been shown to be useful in distinguishing
the presence of particular transcripts that harbor simple repeat
expansions. In cells expressing such mutant RNA, FISH
enables the detection of a variable number of RNA foci scat-
tered throughout the nucleus. By distinguishing mutant and
normal alleles, this technique allows both quantitative analysis
of the ribonuclear inclusions of repeat expansions and their
morphological determination. While DM repeat expansions
accumulate as discrete punctate foci, the CAG and CGG
expansions form bigger and patchy nuclear aggregates. Pre-
sumably the detection of such structures is feasible due to
the increased concentration of mutant transcripts in focal
inclusions, owing to the altered lability and solubility of
expanded repeats and their unspeciﬁc interactions with some
proteins.
This review emphasizes the involvement of nuclear RNA
foci of simple repeat expansions in the pathogenesis of
human hereditary neurological diseases. Ribonucleoprotein
foci of repeated CUG, CCUG, CGG, CAG, AUUCU and
UGGAA motifs present in different human tissues, cultured
cells and several model organisms have been characterized
in detail providing a complex picture of foci morphology,
abundance and molecular composition and their detection
method.
RNA FOCI IN MYOTONIC DYSTROPHIES
DM1 and DM2 are adult-onset muscular dystrophies that
belong to non-coding repeat expansion disorders. A mutation
of the CTG repeat in the 3′UTR of the DMPK gene triggers
DM1 (24,25), whereas an abnormal stretch of CCTG repeats
in intron 1 of the ZNF9 gene causes DM2 (Fig. 1)( 26).
Both diseases are autosomal-dominant genetic disorders with
multisystemic clinical features. In DM1, these features
include progressive weakness and wasting of skeletal and
smooth muscles, myotonia, cataracts, cardiac arrhythmias,
mild mental retardation and endocrinopathies (reviewed in
27,28). Despite some similarities in the major clinical features
between DM1 and DM2, the latter is more benign, and DM2
myopathy is generally not associated with myotonia.
CUG repeat RNA foci in DM1
Normally,theDMPKgenecontains5–37copiesofCTG,butin
DM1 patients, the repeat length reaches several kilobases and
mild myotonic symptoms occur in carriers of as few as 50–
100 copies of CTG (24). The presence of the CTG expansion
leads to nuclear retention of the mutant transcript, and on a cel-
lular level, this retention is manifested by the formation of ribo-
nuclear inclusions called RNA foci (1,13,29). CUG foci have
been most extensively studied in skeletal muscle, which is the
most affected tissue in individuals with DM1 (1,12,20,30).
Foci characteristics include abundance, shape and size, ﬂuor-
escence intensity and colocalization with proteins.
In DM1 biopsies of vastus and derived myoblasts, expan-
sions shorter than 70 copies of CTG are not detected as
nuclear RNA foci, whereas sparse inclusions are formed
when repeats range from 70 to 100 CTGs (20) (Supplementary
Material, Table S1). Studies in MyoD-transformed DM1 ﬁbro-
blasts found that DMPK transcripts with more than 400 CUGs
are completely retained in the nucleus, whereas retention is
incomplete when CUG ¼ 150 (4), and undetectable when
CUG ¼ 80 (31). However, ectopic expression of a DMPK
3′UTR with as few as 57 CTGs in C2C12 mouse myoblasts
was reported to be sufﬁcient for triggering nuclear retention
by means of foci formation (3). The CTG repeat length is
also a factor in determining the number of foci per nucleus
and the fraction of foci-positive nuclei. Botta et al.( 32)
described that, in DM1 biopsy muscle of the vastus lateralis
that expressed 165–430 CUG repeats, RNA foci were
present in about 60% of nuclei, and their number ranged
from 0 to 5 per nucleus, with an average of 1.18 foci. The
number of nuclei without foci decreases with longer CUG
mutations, while the number of foci per nucleus increases.
In muscle expressing 1250–1900 repeats, only 8% of nuclei
have no foci, and up to 18 foci are formed per nucleus, with
an average of 2.92 foci per nucleus (Supplementary Material,
Table S1).
What factors can inﬂuence the abundance of foci upon
expression of DMPK-containing expanded CUG repeats? In
cultured cells, the abundance is dependent on the level of
expression of the mutant transcript, and myotubes have
numerous foci that are larger and brighter than in myoblasts
and ﬁbroblasts harboring the same repeat lengths (12,33,34)
(Fig. 2). Similarly, MyoD-transformed DM1 ﬁbroblasts
contain more CUG RNA foci, which are larger and brighter
than in untransformed cells (2,4). Interestingly, in human
DM1 biopsies of skeletal muscle, fewer nuclear foci are
found than in derived myoblasts and ﬁbroblasts. Numerous
reports have described the presence of only 1–3 intense
CUG RNA foci in myonuclei from skeletal muscle, while
more small foci are found in cultured cells (1,12,20)
(Fig. 2). It has been suggested that tissue freezing or improper
storage may cause RNA degradation and thus give rise to
fewer foci in biopsies, however, Cardani et al.( 35)
3812 Human Molecular Genetics, 2011, Vol. 20, No. 19demonstrated that properly stored and thawed muscles have
similar numbers of foci.
In DM1 patients, the presence of ribonuclear inclusions of
mutant DMPK transcripts has also been shown in non-skeletal
muscle tissues, including the smooth muscle (36) and heart
(29), and in the central nervous system (brain and spinal
cord) (13,19) (Fig. 2). The number and size of RNA foci in
the muscle of the gall bladder and the skeletal muscle of
DM1 patients have been found to be comparable, and 1–2
foci per nucleus were usually detected in both tissues (36).
Another study, performed on paired samples of brain and skel-
etal muscle from the same patients, showed 3.1-fold more foci
in cortical neurons than in muscle (13). The CUG RNA foci
were present in over 85% of cortical neurons, and 30% of
the cells had more than 1 focus; occasionally, there were up
to 15 small foci per nucleus. Except for frontal cortical
neurons, foci were also found in the hippocampus, dentate
gyrus, thalamus, subcortical substantia nigra, brain stem teg-
mentum, white matter and corpus callosum (Supplementary
Material, Table S1).
CUG RNA foci are nuclear structures, however, the
inclusions in dividing cells can also be found in the cytoplasm
(37,38). The toxicity of cytoplasmic foci was studied by
Dansithong et al. (38) in a transgenic DM1 mouse model
designed to express the CTG400 repeat exclusively in the
cytoplasm of cardiac cells. The results of this analysis reveal
that cellular localization of CUG RNA foci is critical for
their deleterious effects, and despite the sequestration of
Mbnl1 by the cytoplasmic aggregates and the elevation of
Cugbp1 levels, no defects in alternative RNA splicing
typical for DM1 were observed in these mice. This result
underlines the signiﬁcance of studies aimed at identifying mol-
ecules that increase the transport rate of the ﬂawed transcript
outside of the nucleus.
Antisense technology has been employed to disrupt CUG
RNA inclusions by targeting the mutant DMPK transcript
and preventing its interaction with host cell proteins. Direct
administration of morpholino oligonucleotides (39) and
2′-O-methyl-phosphorothioate-modiﬁed (CAG)7 AON (anti-
sense oligonucleotides) (40) into DM1 mouse skeletal
muscle has been described to be effective in reducing the
number of ribonuclear aggregates and in normalizing the
effect on aberrant pre-mRNA splicing (Supplementary
Material, Table S1). Similar conclusions were derived from
work in human DM1 myoblasts with the use of engineered
human U7 small nuclear RNAs (hU7-snRNAs) containing a
poly-CAG antisense sequence (41). Furthermore, employment
of a nuclear-retained hammerhead RNA (ribozyme) designed
to cut the 3′UTR of DMPK mRNA (42) and the use of penta-
midine, a small molecule that partially targets CUG repeats
and releases MBNL1 (43), were reported to result in the
destruction of nuclear DM1 foci.
CCUG repeat RNA foci in DM2
In DM2, the expression of an enormous expansion of tetranu-
cleotide repeats in the ZNF9 gene leads to the formation of
nuclear CCUG RNA foci as a result of the aberrant degra-
dation of an intronic sequence (26). In skeletal muscle, the
length threshold for nuclear retention and foci formation is
Figure 1. Simple repeat expansions associated with human neurodegenerative and neuromuscular disorders; mechanisms of pathogenesis mediated by protein
loss-of-function (white) and protein and RNA toxic gain-of-function (yellow).
Human Molecular Genetics, 2011, Vol. 20, No. 19 3813Figure 2. Representative images of FISH RNA depicting nuclear RNA foci in various tissues and cultured cells expressing CUG, CCUG, CAG, CGG, AUUCU
and UGGAA repeat mutations. (1A) Nucleus of human muscle ﬁber with CUG foci (20) (1B) CUG foci in a gallbladder from a DM1 patient (36) (1C) CUG foci
in post-mortem cardiac tissue colocalizing with MBNL2 (29) (1D) CUG inclusions in frontal cortical neurons of a human DM1 brain (13) (1E) small nuclear
CUG foci in Purkinje cells from a DM1 brain (13) (2A) ribonuclear CUG foci in DM1 myoblasts (12) (2B) and (2C) CUG nuclear foci in DM1 ﬁbroblasts
without MyoD (B) and with MyoD (C) (2) (2D) nuclear CUG foci in skeletal muscle from HSA
LR-20b DM1 mice (20) (2E) nuclear CUG foci in skeletal
muscle from transgenic CTG200 mice (45) (3A) nuclear and cytoplasmic RNA foci in C2C12 cells ectopically expressing 200 CUG from 3′UTR DMPK
(37) (3B) nuclear RNA foci in COS7 cells expressing 960 CUG repeats (21) (3C) nuclear CUG foci in the larval muscle of DM1 Drosophila (46) (3D)
CUG foci in the nuclei of the body wall muscle cells from DM1 Drosophila (47) (3E) nuclear RNA foci formed by 270 CUG repeats expressed in Drosophila
(48) (4A) CCUG nuclear inclusion in human DM2 skeletal muscle (12) (4B) CCUG focus in the left ventricles of an autopsy heart (49) (4C) CCUG foci in
human homozygous DM2 myoblasts (10) (4D) CUG foci in Purkinje cells from a human SCA8 cerebellum (7) (4E) CUG foci in Purkinje cells from SCA8
BAC mice (7) (5A) nuclear CUG foci in HEK293 cells expressing an ATXN8OS mutant transcript (50) (5B) CUG nuclear foci in a HDL2 cerebral frontal
cortex (6) (5C) CUG foci in HDL2 stratum (6) (5D) CAG nuclear aggregates in human HD ﬁbroblasts (23) (5E) nuclear CAG foci in muscle sections from
CAG200 mice (22) (6A) RNA foci in C2C12 cells ectopically expressing 200 CUG colocalizing with MBNL (22) (6B) nuclear foci in COS7 cells expressing
960 CAG repeats (21) (6C) nuclear RNA foci formed by CAG270 expressed in Drosophila (48) (6D) nuclear signal from 5′UTR antisense riboprobe in isolated
nuclei of the frontal cortex from post-mortem FXTAS brain (51) (6E) nuclear aggregate of CGG repeat mutation sequesters Sam68 protein in a post-mortem
FXTAS brain section of the hippocampal area (5) (7A) nuclear CGG foci in brain sections from mice expressing 98 CGG repeats colocalizing with Sam68 (5)
(7B) nuclear RNA aggregates in COS7 cells expressing 100 CGG repeats (5) (7C) nuclear and cytoplasmic AUUCU aggregates in SCA10 human ﬁbroblasts (9)
(7D) nuclear and cytoplasmic RNA aggregates in brains from mice expressing expanded AUUCU repeats (9) (7E) nuclear RNA foci in SCA31 Purkinje cells (8).
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sively of non-coding CCUG repeat expansions and do not
contain other parts of intron 1 of ZNF9 (10). This feature is
in contrast to DM1, in which the entire DMPK transcript loca-
lizes to CUG foci (1). How does this difference affect foci
size? Do larger DM2 mutations reaching up to 11000
CCTG, and the 8- to 14-fold higher expression level of
ZNF9 mRNA than DMPK mRNA in muscle cells affect the
abundance of the RNA foci? The results reveal that in
human DM1 and DM2 skeletal muscles, the numbers of
RNA foci are comparable and range from 0 to 5 per
nucleus, however, DM2 inclusions are bigger and more
intense (8- to 13-fold) than DM1 inclusions (12) (Supplemen-
tary Material, Table S1). The inclusions differ by shape, and
whereas DM1 foci are spheroidal, DM2 foci are rod-shaped
(Fig. 2). Additionally, the extent of MBNL1 depletion from
the nucleoplasm and its accumulation in ribonuclear foci is
more extensive in DM2 than in DM1 (30,52).
The differentiation of DM muscle cells is correlated with a
decrease in the number of nuclear foci and an increase in their
size. DM2 myoblasts from biceps brachii expressing 1000–
2500 CCTG repeats have 3–25 foci per nucleus, with an
average of 14 foci, while myotubes have fewer but larger
and more intense inclusions (35). The presence of cytoplasmic
DM2 foci has not been reported in muscle tissue and derived
cultured cells (26,35,53).
Protein components of RNA nuclear inclusions in DM
In 2000, Swanson and colleagues (2) presented the ﬁrst exper-
imental evidence that triplet repeat expansion RNA-binding
proteins (EXP), homologous to the Drosophila mbl proteins,
bind preferentially to CUG repeat RNA in a length-dependent
manner. The authors reported that the EXP protein itself forms
nuclear foci in MyoD-transfected DM1 ﬁbroblasts, and that
their number per nucleus ranged from 6 to 30, with an
average of 15 foci (Supplementary Material, Table S1). The
biological signiﬁcance of the interaction between repeat
RNA and the MBNL-family proteins has been manifested
through the disruption of alternative splicing, which is a
characteristic feature of DM pathogenesis. Muscle wasting
and weakness, heart problems and insulin resistance are
associated with aberrant alternative pre-mRNA splicing and
inappropriate expression of fetal isoforms of CLCN1, INSR
and TNNT2 in adult DM tissues (19,54,55).
RNA-binding proteins of the muscleblind-like family,
MBNL1, MBNL2 and MBNL3, when either endogenous or
exogenously expressed, are sequestered by expanded repeats
trapped in nuclear foci. Experimental evidence has revealed
the presence of MBNL-positive CUG and CCUG RNA foci
in biopsy tissues from skeletal and smooth muscles and in
derived cultured cells (12,14,20,30,36,41,52), as well as in
cardiac (29) and neuronal cells (13,19) (Supplementary
Material, Table S1). Interestingly, as shown in DM2 cultured
muscle cells, not all CCUG RNA foci are enriched with
muscleblind 1, although each MBNL focus overlaps with the
repeat inclusion (35,52).
Cellular RNA-binding proteins may inﬂuence the structure
of RNA and its trafﬁcking. Several dsRNA-binding proteins
and other RNA interacting proteins have been analyzed for
their colocalization and sequestration by DM nuclear RNA
foci. Among them are CUGBP1, hnRNPs (A1, C1/C2, C, H,
F and M), TRBP, PKR, PACT, NF90 and RHA, all of
which do not recapitulate the MBNL feature of sequestration
by the expanded RNA (2,12–14,29,56,57) (Supplementary
Material, Table S1). Some of the proteins are recruited to
DM1 foci and colocalize with them to a limited extent. This
behavior is also true for the hnRNP H and hnRNP F proteins,
which colocalize with CUG foci in human muscle and brain
cells, components of the proteosome (20Sa, 11Sg and 11Sa
subunits) recruited to the foci in cortical neurons (13,16) and
the Y12, Y14 and 9G8 proteins associated with CUG RNA
foci in human myoblasts and ﬁbroblasts (14). For SC-35, a
marker of splicing speckles, experimental results showed no
overlap with CUG and CCUG RNA foci and only a close
association and some random coincidence with the nuclear
inclusions (1,14,15,17) (Supplementary Material, Table S1).
CUG RNA foci in DM1 model organisms
In 2000, Thornton and colleagues (58) published the ﬁrst
transgenic DM1 mouse model carrying an untranslated 250
CTG repeat under the human skeletal actin promoter (HSA).
These mice develop skeletal muscle myotonia and myopathy
and accumulate numerous CUG RNA foci in myonuclei. It
was shown that over 50 foci per nucleus can be formed in
the mouse muscle, and that the foci are Mbnl1-positive
(12,39,40). Other transgenic DM1 mouse models are inducible
models that express 960 CTG repeats speciﬁcally in the heart
(59) or skeletal muscle (60) or 200 CTG in both of these
tissues (45). Formation of RNA foci that colocalize with
Mbnl1 was reported in all of these models, but the abundance
of ribonuclear inclusions depends on the transgene expression
levels. Cooper and colleagues (59) showed that, in mouse
hearts from the highest-expressing line, a greater fraction of
nuclei contained foci than in the moderate-expressing line
and that, in the former, multiple foci per nucleus are formed,
whereas only single foci per nucleus are usually formed in
the latter (Supplementary Material, Table S1). Mahadevan
et al. (45) observed the DM1 phenotype of skeletal and
cardiac muscles, including aberrant splicing, in both foci-
positive DMPK 3′UTR-(CTG)200 expressing mice and litter-
mates who overexpressed (CTG)5 in the absence of detectable
foci. Their results raise the question of whether the presence of
RNA inclusions is required for the development of DM1 fea-
tures. In addition, results from transgenic CUGBP1 mouse
models (61,62) and knockout Mbnl1 mice (63), both lacking
RNA foci but having aberrant splicing, demonstrate that foci
formation and aberrant splicing are independent events and
that some core features of DM1 do not depend on the presence
of either foci or deviated alternative splicing.
In the transgenic DM1 Drosophila models published thus
far, RNA foci were formed with CTG ≥ 162 repeats
(46,47,64,65) (Supplementary Material, Table S3). In the
ﬁrst ﬂy model, Monckton and colleagues (47) described the
presence of dynamic and transient CUG RNA foci with a
short half-life, the formation of which is not supported by
all cell types. The number and intensity of the inclusions
increase throughout the larval stages of development and
then decrease during pupation, when the muscle remodels.
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expression, RNA foci are restricted to abdominal, cranial
and pleurosternal muscles and are absent in legs and indirect
ﬂight muscles. CUG foci were not found in the nuclei of the
salivary gland, brain and peripheral nervous system at any
stage in larvae to adults (47). From this work, it was concluded
that the expression of expanded CUG repeat RNA is not sufﬁ-
cient to drive foci formation, indicating a requirement for cell-
speciﬁc factors. The presence of ribonuclear foci was also
described in three other DM1 ﬂy models that expressed inter-
rupted 240 and 480 CTG expansions (46,64,65) (Supplemen-
tary Material, Table S3). In DM1 Drosophila models,
muscleblind type 1 protein colocalizes with CUG foci. The
number of RNA inclusions per nucleus decreases in ﬂies
co-expressing MBNL1 and increases when CUGBP1 is
co-expressed with the CUG repeat mutation (46).
CUG RNA FOCI IN SCA8
SCA 8 is autosomal dominant inherited disease of the central
nervous system caused by a CTG/CAG trinucleotide repeat
expansion. Bidirectional transcription has been shown in
SCA8 because two genes that span the repeat region are
expressed in opposite directions (66). The ATXN8 gene on
the antisense strand encodes a nearly pure polyglutamine
(poly-Q) protein in the CAG direction, and the ATXN8OS
gene on the sense strand encodes an untranslated CUG expan-
sion RNA. In normal individuals, the length of the CTG repeat
is 16–34, whereas it is .74 in affected individuals. SCA8
leads to the impairment of speciﬁc nerve ﬁbers carrying mess-
ages to and from the brain, resulting in degeneration of the cer-
ebellum with variable involvement of the brainstem and spinal
cord.
In 2009, Ranum and colleagues (7) demonstrated that in
SCA8 the expression of sense strand repeats is associated
with nuclear retention of the transcript, resulting in CUG
foci formation as detected in patient post-mortem brains and
SCA8 BAC transgenic mice (Fig. 2). CUG ribonuclear
inclusions vary in size, number and distribution in different
brain regions and among brain samples. In human cerebellar
tissue in cases with 109 CTG repeats, the CUG foci are only
detected in single molecular layer interneurons. In cases
with 400 and 1000 CTG, single foci are found in the nuclei
of molecular layer interneurons and the Bergmann glia sur-
rounding the Purkinje cells in the granule cell layer, whereas
multiple nuclear foci are detected in the Purkinje cells (Sup-
plementary Material, Table S2). In SCA8 BAC Tg mice
expressing 116 CTG repeats, foci have similar distributions
in the cerebellar cortex as in human brains with 400 and
1000 repeats (7).
In cerebellar sections of human and mouse SCA8 samples,
CUG RNA foci co-localize with MBNL1 in molecular layer
interneurons. Interestingly, in Purkinje cells, where MBNL1
is predominantly expressed in the cytoplasm, the nuclear
RNA foci are MBNL1-negative (7), indicating that expression
of the SCA8 mutation does not trigger the intracellular trans-
location of MBNL1 and its accumulation in the nucleus where
it could amplify the toxicity of CUG RNA foci.
CUG RNA FOCI IN HDL2
Nuclear RNA inclusions resembling those in DM1 brains are
detected in HDL2 brains but with relatively short CUG
repeat expansions. HDL2 is an autosomal dominant and
adult-onset neurodegenerative disease caused by a CTG
repeat expansion located in the variably spliced exon 2A of
the JPH3 gene (Fig. 1). However, most recent results from
BAC transgenic mouse models of HDL2 have provided
some evidence to consider the disease also a polyglutamine
disorder with bidirectional transcription similar to what is
found in SCA8 (67). The repeat length in healthy individuals
ranges from 6 to 28 triplets, whereas HDL2 symptoms develop
with 40–59 repeats. Pathological features of HDL2 include
cortical and basal ganglia degeneration and a loss of medium-
size neurons in the striatum in a dorsal-to-ventral gradient.
In the frontal cortex and striatum of HDL2 patient brains,
untranslatable JPH3 transcripts with CUG repeat expansions
are found in ribonuclear inclusions (Fig. 2). The RNA foci
include, in addition to CUG repeats, other parts of the JPH3
message with sequestered MBNL1. Margolis and colleagues
(6) reported that an abundance of foci in post-mortem HDL2
brains correlates with CTG repeat length, and shorter repeats
give rise to fewer riboinclusions. In the frontal cortex in
cases with 51–55 CTG, about 30% of neurons contain foci;
most of the neurons have more than one focus, with as
many as 13 foci per nucleus. However, in the striatum,
which is the most severely affected brain region in HDL2,
about 15–20% of neurons have 5–20 foci, which appear
brighter than those in the cortex (6). In dentate nuclei of the
cerebellum and hippocampus, foci are found only occasion-
ally, in ,5% of neurons (Supplementary Material, Table S2).
In HEK293 and HT22 cells, overexpression of truncated
JPH3 with exon 2A harboring untranslated 53 CTG repeats
was shown to be toxic to the cells and led to the formation
of RNA inclusions. Nuclear CUG inclusions are also found
in brains of BAC transgenic mice of HDL2 where some of
the RNA foci colocalize with nuclear inclusions positive for
ubiquitin and immunoreactive with polyQ antibodies (67). In
all these cells, CUG foci colocalize with both endogenous
and exogenous MBNL1. The presence of MBNL1 is also
detected in foci of the frontal cortex of HDL2 patients,
however, alternative splicing of APP and MAPT genes,
although somehow deviated, is less pronounced than in DM1
(13). Together, these results indicate that expanded CUG
repeats in the size range of the HDL2 mutation can be toxic
to various mammalian cells (6).
CGG RNA FOCI IN FXTAS
FXTAS is a common genetic disease of the central nervous
system that results from an expansion of CGG repeats from
6–54 copies to 55–200 repeats located in the 5′UTR of the
fragile X syndrome gene FMR1 (Fig. 1). All individuals
with FXTAS are carriers of a pre-mutation of the FMR1,
and the full mutation of this gene with more than 200
repeats results in fragile X mental retardation syndrome
(FXS) (68). Carriers of the pre-mutation may have some fea-
tures of the FXS phenotype, including progressive cerebellar
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symptoms and brain atrophy (69).
In FXTAS brains, the expression of CGG repeat expansion
is associated with the formation of ubiquitin-positive intranuc-
lear inclusions (70). It was therefore asked whether the elev-
ated levels of FMR1 mRNA that are found in pre-mutation
carriers have a cumulative toxic effect, leading to the for-
mation of RNA inclusions. In 2004, Hagerman and colleagues
(51) identiﬁed the presence of FMR1 mRNA within the intra-
nuclear inclusions isolated from the frontal cortex of FXTAS
post-mortem human brains (Fig. 2). A single-spot signal of
enlarged size was detectable in the nuclei with each of three
antisense riboprobes targeting either coding or non-coding
(5′UTR and 3′UTR) portions of the FMR1 message (Sup-
plementary Material, Table S2). The inclusions, however,
were found only in a subgroup (6–11%) of the analyzed
nuclei. These results provided some evidence to indicate that
FXTAS is an RNA-mediated disease. However, a later
report by Sellier et al. (5) demonstrated that an RNA
gain-of-function mechanism and spliceopathy are also features
of FXTAS pathogenesis. As shown, expanded FMR1 repeats
of pre-mutation lengths are retained in the nuclei of FXTAS
post-mortem brains and in the brains of transgenic mice that
express 98 CGG repeats. Additionally, ectopic expression of
FXTAS repeats in a variety of cells results in the formation
of enlarged aggregates, which are dynamic and increase over
time (Fig. 2). Interestingly, while PC12, COS7 and SKOV3
cells can support the formation of CGG inclusions, they are
not formed in HeLa, HEK293, Neuro-2a and SK-N-MC cells.
In cells expressing expanded CGG repeat RNA, the for-
mation of enlarged foci is associated with the recruitment
variety of RNA-binding proteins, including Sam68, hnRNP
G and MBNL1. Surprisingly, although MBNL1 is employed
as a foci constituent, its free-pool functional level is not
exhausted, and there is no aberrant splicing alteration of
MBNL1-sensitive genes in expanded CGG repeat-expressing
cells. Nevertheless, spliceopathy typical for DM1 has been
observed in cells expressing the FXTAS mutation, where a
subset of Sam68-sensitive genes is aberrantly spliced (5).
NUCLEAR CAG RNA FOCI
Expansions of CAG repeats are associated with a group of
dominantly inherited neurological disorders known as poly-
glutamine diseases represented by spinocerebellar ataxias
type 1, 2, 3, 6, 7 and 17, Huntington’s disease (HD),
dentatorubral-pallidoluysian atrophy and spinal and bulbar
muscular atrophy (Fig. 1). Causative CAG mutations are
located in the coding sequences of single unrelated genes
and their translation gives rise to polyglutamine-rich proteins.
These disorders are characterized by variable degrees of
degeneration in the cerebellum, spinocerebellar tracts and
brain stem neurons (reviewed in 71).
In CAG repeat expansion diseases, the presence of coding
mutation may confer toxicity to the mutant transcripts and to
encoded poly-Q proteins. However, the most studied mechan-
ism of pathogenesis is centered on the aberrant ability of
mutant proteins to attract cellular proteins, such as ubiquitin,
HSP70, proteosome proteins and transcription factors, which
leads to the formation of nuclear and cytoplasmic inclusion
bodies (reviewed in 71). A role for mutant CAG repeat
RNA in poly-Q disorders has been increasingly recognized
over the past few years, with experimental evidence revealing
its toxic capacity. The results of the studies in human (23) and
primate cells (21) and in transgenic ﬂy (48), worm (72) and
mouse (22) models unequivocally demonstrate that expanded
CAG RNA exhibits some toxic features and therefore could
be considered an auxiliary toxic agent (reviewed in 73).
In human HD and SCA3 ﬁbroblasts, endogenous expression
of HTT and ATXN3 mutant transcripts has recently been cor-
related with the formation of enlarged nuclear aggregates that
are composed of CAG repeat-containing RNA and MBNL1
protein (23) (A. Mykowska et al., manuscript in preparation).
Similar phenomena were observed in primate cells ectopically
expressing large and interrupted CAG960 repeat RNA (21).
COSM6 cells were found to support the formation of
nuclear MBNL1-positive CAG RNA foci with an average
number of 13 per nucleus; for comparison, there were 11
RNA inclusions per cell when CUG960 repeats were
expressed in COSM6 cells (Supplementary Material,
Table S2).
Work in transgenic model organisms bearing untranslated
and pathogenic-length CAG repeats revealed the formation
of intranuclear RNA inclusions and the occurrence of
various abnormalities in the eye, nervous system
and muscle, which are not observed in control littermates.
In Drosophila, the toxic effect of CAG RNA was repeat-length
dependent, and the loss of neuronal integrity detectable with
100 CAG repeats was elevated with 250 CAG repeats (48).
Interestingly, overexpression of MblA caused enhanced neuro-
toxicity, correlated with an increased level of non-coding
RNA. Nuclear foci of CAG250 RNA, which were detected
in a limited number of cells, were smaller than the robust
foci of CUG repeat RNA observed in these ﬂies (Fig. 2). In
mouse (22) and Caenorhabditis elegans (72) models, the
expression of CAG expansions was correlated with pathogenic
changes in muscle structure and function, shortened life span
and decreased brood size. In mouse muscle, 200 CAG-
containing transcripts accumulated in punctate nuclear RNA
foci that sequester MBNL1. Similarly, in C2C12 myoblasts,
CAG RNA inclusions are formed after the expression of
either 200 or 58 repeats. The abundance of these foci is
repeat-length dependent, and twice as few inclusions are
formed with 58 CAG repeats than with 200 repeats (3.4 and
6.7 foci/nucleus, respectively) (22). The repeat length,
however, does not inﬂuence the proportion of foci-positive
nuclei. In the CAG58 line, 13.6% of nuclei are foci-positive
compared to 17.4% of nuclei in the CAG200 line. No differ-
ence in foci number per nucleus was found when comparing
CAG200- and CUG200-expressing cells (Supplementary
Material, Table S2). In C. elegans, expression of either
CAG125 or CUG125 repeats in muscle results in the for-
mation of nuclear RNA foci that are of similar size. Both
types of foci recruit C. elegans muscleblind protein
(CeMBL), and  92% of CAG RNA foci and 60% of CUG
foci are enriched with CeMBL. In expanded CAG
worms, the overexpression of CeMBL partially reverses the
repeat-triggered pathogenesis, as does knock-down of
repeat expression with siRNA (72). Thus, toxicity of CAG
repeat RNA seems to be expressed by compromising
Human Molecular Genetics, 2011, Vol. 20, No. 19 3817CeMBL function, which is in agreement with results obtained
in a variety of cells that express mutant CUG repeat RNA.
RNA FOCI IN SCA10 AND SCA31
SCA10 is an autosomal dominant neurodegenerative disease
of the central nervous system with progressive impairment
of speciﬁc nerve ﬁbers leading to the degradation of cerebel-
lum. The disease-causing mutation is an enormous expansion
of a tandem 5-base ATTCT unit present in intron 9 of the
ATXN10 gene (reviewed in 74). In normal individuals, the
repeat ranges from 10 to 29 and increases up to 4500 in
SCA10 patients.
The pathomechanism of SCA10 has been associated with
the expression of expanded AUUCU repeat RNA, and the
mutant ATXN10 transcript was shown to be the principal mol-
ecule capable of triggering neuronal death in SCA10 (9). The
mutant RNA expression is associated with the activation of
apoptosis and the functional inactivation of the hnRNP K
protein, which interacts in situ with AUUCU repeat expan-
sions. The intronic AUUCU repeat mutation is properly
spliced out but becomes resistant to degradation and is depos-
ited as numerous aggregates in nuclei and cytoplasm in
SCA10 cells. Their presence was shown in SCA10 human
ﬁbroblasts and in cells ectopically expressing untranslated
AUUCU repeat expansions (9) (Fig. 2). Additionally,
SCA10-like aggregates were detected in the brain of trans-
genic mice expressing  500 AUUCU repeats from the
b-globin intron sequence, and their abundance was higher in
6-month-old mice than in 3-month-old mice (Supplementary
Material, Table S2). Collectively, these results show that the
vast SCA10 intronic repeat mutation develops a resistance to
degradation and forms insoluble nuclear aggregates similar
to the DM2 repeat mutation.
SCA31 is an adult-onset autosomal-dominant neurodegen-
erative disorder with progressive cerebellar ataxia mainly
affecting Purkinje cells. This disease is associated with a pen-
tanucleotide (TGGAA)n repeat expansion, ranging from 2.5 to
3.8 kb in length and spanning two genes, TK2 and BEAN,
which are transcribed in opposite directions. Intranuclear
RNA foci bearing sense transcripts of BEAN that contains
the (UAAAAUAGAA)n repeat were detected in SCA31 Pur-
kinje cells in which about 30–50% of nuclei were foci-
positive (Fig. 2). RNA foci were not detected with a probe
for the antisense (UUCUAUUUUA)n repeat corresponding
to the TK2 transcript (Supplementary Material, Table S2) (8).
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
This review article brings together comprehensive information
regarding nuclear foci formed by transcripts of different
mutant genes that contain simple sequence repeat expansions
and are implicated in the pathogenesis of human hereditary
neurological diseases (Fig. 1). It appears that nuclear RNA
foci are formed by transcripts harboring different types of
repeated motifs, including CUG, CCUG, CGG, CAG,
AUUCU and UGGAA of different lengths and expression
levels (Fig. 2). We provided detailed characteristics of these
foci present in different human tissues and cultured cells and
in several model organisms. The foci characteristics include
their detection method, morphology, abundance and molecular
composition (Supplementary Material, Tables S1, S2 and S3).
The picture that emerges from this analysis shows the current
state of research on ribonuclear foci, reveals areas of more and
less developed research, and allows the pinpointing of some
issues that need to be resolved.
It is known that development and progression of RNA-
mediated pathology involve expression of expanded repeats
(5–7,21,22,75) and the presence of mutant transcript is
required to drive RNA foci formation (9,10,37,58). These
microscopic RNA structures are found in all cases in which
pathology develops and thus are linked to the degeneration
process. However, this is still a matter of debate whether
RNA foci are a cause of pathology or they are epiphenomena
which accompany other symptoms of pathogenesis. Our
present knowledge speaking in favor of toxicity of nuclear
RNA foci is mostly based on their propensity to affect essen-
tial alternative splicing factors causing their sequestration, and
compromising their functionality in pre-mRNA processing
(2,20,43). One might speculate, however, that the real situ-
ation is more complex and the RNA foci might be considered
a sink for at least temporary immobilization of many other
proteins. One could also imagine putative toxic interactions
of mutant transcripts with cellular proteins that occur outside
of foci and are triggered by soluble fraction of transcripts. In
such scenarios, complexity and variability of symptoms
associated with RNA repeat-mediated mechanisms could be
explained by differences in protein-binding properties of
different repeats and heterogeneity of protein environment in
different tissues.
For almost two decades, detection of nuclear repeat expan-
sions has been conducted with FISH, as initially described by
Singerand colleagues(1)with some minor modiﬁcations.Anti-
sense probes used in FISH varied in repeat length, type and
number of ﬂuorescent labels and the presence of backbone
modiﬁcations, such as PNA or LNA, and were used to
enhance the binding efﬁciency and sensitivity of transcript
detection. However, these differences in detection method are
unlikely to be responsible for the foci diversity presented here,
and most of these varieties must have biological sources. In
general, brighter foci detected by FISH are indicative of a
higher number of repeats because a greater number of probe
molecules hybridize to a target, thereby yielding a strong and
clearly distinguishable signal. For example, this phenomenon
occurs inDM1andDM2,whichare causedby severalhundreds
or thousands of repeated units present in the transcripts.
As shown in Supplementary Material, Tables S1 and S2,
RNA foci associated with DM1 pathogenesis are the best
characterized. The studies on DM2, SCA8 or FXTAS foci
are less advanced, and the characterization of nuclear RNA
inclusions in cells with CAG repeat expansions that contribute
to the pathogenesis of polyglutamine diseases has just begun.
Distinct features of the different repeat RNA foci observed in
various tissues include their abundance and characteristic mor-
phology (Fig. 2). While DM expansions accumulate as dis-
crete punctate inclusions with sizes and numbers that are
somehow related to the expression levels of the mutant tran-
script, the CAG expansions seem to aggregate as bigger
3818 Human Molecular Genetics, 2011, Vol. 20, No. 19splotches, similar to what is found in expanded CGG expres-
sing cells. The repeat RNA sequence, its secondary structure
and the host cell protein environment might modulate
nuclear foci morphology. Importantly, the majority of tran-
scripts containing different types of repeats colocalize robustly
with MBNL1. It is conceivable that other proteins that have
been detected to overlap with foci to some extent or to
closely juxtapose with them represent transient and secondary
protein–protein interactions. The functions of such proteins do
not seem to be severely compromised, as with MBNL1, but
their activity is somehow modiﬁed, as recently reported in
FXTAS (5). It is of importance to resolve the relationship of
repeat RNA foci with known nuclear bodies, such as splicing
speckles and paraspeckles, which look similar to the RNA foci
described for CGG and CAG repeat expansions under the
microscope. This association was previously investigated for
DM1 and DM2 mutations (1,14,15,17,47).
Therefore, studies in a broader range of cells and tissues
combined with careful foci characterization will be essential
to explain issues such as cellular factors, which are necessary
for foci formation, foci morphology, abundance and their mol-
ecular composition. This issue applies to all diseases in which
RNA toxicity is involved and to different tissues in which
mutant RNA is expressed, not just to tissues in which pathol-
ogy primarily develops. In the scope of this analysis is also the
importance of careful RNA sequencing studies, given the
recent discovery that antisense transcription is more ubiqui-
tous than originally thought and since the presence of anti-
sense transcripts has been demonstrated for many genes
harboring trinucleotide repeat expansions associated with
human neurological disorders (reviewed in 76). In two of
them, SCA8 and HDL2, the CAG antisense transcripts seem
to be additional sources of cellular toxicity (66,67). A compre-
hensive analysis of these factors may contribute to a better
understanding of the complexity of diseases in tissues affected
by pathological processes.
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